Description: MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
Home Page: www.maatpharma.com
70 Avenue Tony Garnier
Lyon,
69007
France
Phone:
33 4 28 29 14 00
Officers
| Name | Title |
|---|---|
| Mr. Herve Affagard | CEO, Co-Founder & Director |
| Dr. Joel Dore Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Mr. Pierre Rimbaud | Co-Founder |
| Ms. Sian Crouzet | COO & CFO |
| Ms. Carole Schwintner | Chief Technology Officer |
| Dr. Nathalie Corvaia Ph.D. | Chief Scientific Officer |
| Dr. Savita Bernal Ph.D. | Chief Bus. Officer |
| Ms. Isabelle Adeline M.B.A., Pharm.D. | Chief of Staff |
Exchange: PA
Country: FR
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.6996 |
| Price-to-Sales TTM: | 83.2253 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 46 |